GLPwatch
Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?
JAAPA · 2024
Last updated 2026-05-28GLP-1 drugs help lower blood sugar control and reduce weight in people with type 2 diabetes. The article reviews how to choose the right drug based on evidence, but it does not provide specific details on which drugs were studied or how much they helped.
AI summary of the abstract below.
| Journal | JAAPA, 2024 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Glucagon-like peptide 1 agonists (GLP1s) and the novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 agonist are effective drugs for reducing A1C and weight in patients with type 2 diabetes. However, clinicians may find it difficult to discern which drug to prescribe in specific clinical scenarios. This article discusses evidence-based clinical use of these drugs.
Verbatim abstract via PubMed 38662894 ↗